Elaine V. Jones

Elaine V. Jones, Ph.D. is an accomplished biopharmaceutical executive with more than 20 years of life science investing experience. She has served on over 35 life science company boards and has both biopharma research and business development expertise. Dr. Jones currently serves as a Director on the boards of CytomX Therapeutics (NASDAQ: CTMX), Gritstone Oncology (NASDAQ: GRTS), and NextCure (NASDAQ: NXTC). She also serves on the Board of the Novartis Venture Fund and acts as an advisor to BiovelocITA, the first Italian incubator dedicated to biotech companies. Until April 2019, Dr. Jones was Vice President, Venture Capital, at Pfizer Ventures (PVI). During her 10 years there, she was responsible for making and managing venture investments in areas of strategic interest for Pfizer. Dr. Jones served as PVI’s representative to the Board of Directors for >20 companies, including recent roles at Arrakis, Kymera Therapeutics, MISSION Therapeutics (UK), NextCure, and Nimbus. Prior to Pfizer, Dr. Jones was a General Partner with the venture fund, EuclidSR Partners. Dr. Jones began her investing career in 1999 at S.R. One, GlaxoSmithKline’s corporate fund. Previously, she served as Director, of Scientific Licensing for SmithKline Beecham and was a research scientist in SmithKline Beecham Pharmaceutical R&D. Dr. Jones is a graduate of Juniata College, received her Ph.D. in Microbiology from the University of Pittsburgh, and conducted post-doctoral research at the National Institutes of Health.